Nuvation Bio Inc. (NUVB) compared with its closest peers (FBIO, TNGX, DERM, ENTA, AYTU). Peer set by Pharmaceutical Products; 10 comparable drugmakers. First-party data.
Fortress Biotech, Tango Therapeutics, Journey Medical, Enanta Pharmaceuticals, Aytu BioPharma, Kura Oncology, Rockwell Medical, Nektar Therapeutics, Agios Pharmaceuticals and Q32 Bio share Nuvation Bio's sub-industry, pharmaceutical makers.
| Company | Market Cap | P/E |
|---|---|---|
| Fortress Biotech, Inc. (FBIO) | $95.44M | 0.9 |
| Tango Therapeutics, Inc. (TNGX) | $3.46B | -10.2 |
| Journey Medical Corporation (DERM) | $213.21M | -16.4 |
| Enanta Pharmaceuticals, Inc. (ENTA) | $390.28M | -2.8 |
| Aytu BioPharma, Inc. (AYTU) | $25.12M | -1.0 |
| Kura Oncology, Inc. (KURA) | $1.06B | -3.3 |
| Rockwell Medical, Inc. (RMTI) | $315.76M | — |
| Nektar Therapeutics (NKTR) | $2.53B | -4.3 |
| Agios Pharmaceuticals, Inc. (AGIO) | $1.97B | -3.8 |
| Q32 Bio Inc. (QTTB) | $270.79M | 1.4 |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.2 |
NUVB overview · NUVB earnings · NUVB financials · NUVB KPIs · NUVB documents · NUVB ownership
Data sourced from U.S. SEC EDGAR filings and market data. Not personalized investment advice.